Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 3Thoracic 1

Conditions

Anemia 2Renal Anemia 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 3167Cisplatin 3163Carboplatin 2940Paclitaxel 2675Radiotherapy 2648Gemcitabine 2548pembrolizumab 2334Docetaxel 2158Bevacizumab 2129Fluorouracil 1822Capecitabine 1785Oxaliplatin 1713Dexamethasone 1591Nivolumab 1517Doxorubicin 1479Rituximab 1455Etoposide 1342Magnetic Resonance Spectroscopy 1270Irinotecan 1235Leucovorin 1217Cytarabine 1124Pemetrexed 1064Drug Therapy 1062fludarabine 1052Vincristine 958Specimen Handling 940Prednisone 927Cetuximab 921Lenalidomide 917Trastuzumab 903

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × continuous erythropoietin receptor activator × Clear all
NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Hoffmann-La Roche

Phase 2 Completed
64 enrolled 15 charts 1 FDA
Classical hematology

Renal Anemia

NCT00327535 2016-08-11

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Hoffmann-La Roche

Phase 2 Completed
153 enrolled
Classical hematology

Anemia

NCT00072059 2013-07-18

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡